Genitourinary Cancer

Real-World HRQOL Findings Support Nivolumab for Previously Treated mRCC

September 19, 2022

Results of retrospective analysis of previously treated patients with metastatic renal cell carcinoma who received nivolumab in the second- and third-line showed that health-related quality of life was maintained in the real-world setting